Department of Neurology
Clinical Trials
Information on grant-funded research and multi-center clinical trials.
Clinical Trials
Information on grant-funded research and multi-center clinical trials.
Original Grant-Funded Research
| Name | Description and Contact Info |
|---|---|
| Memory Disorders/Alzheimer's Disease | If you're interested in participating in one of our research trials, please contact Terry Fogerty at (401) 606-4664 or email memory@lifespan.org |
| Blood-brain Barrier Disruption As a Biomarker For Perioperative Neurocognitive Disorder: Cognitive Recovery After Elective Surgery | The objective of this research is to investigate the extent to which an innovative brain imaging technique, water exchange index MRI evidence of blood-brain barrier dysfunction predicts the incidence of post-operative cognitive decline and dementia, in a longitudinal study of older adults undergoing major elective non-cardiac surgeries. This research will lay the essential groundwork for development of future interventions to improve the cognitive safety of major elective surgeries in the aging population. Recognition of blood-brain barrier dysfunction may be of critical prognostic importance in determining brain susceptibility to surgical stress. For questions, please contact Lori_Daiello@brown.edu |
| Combined EEG and Pupilometry Measures of Language Processing As Markers For Early Detection of Alzheimer's Disease | This study exploits recent advances in cognitive neuroscience to develop novel probes that are sensitive to both the earliest cognitive changes in AD and the compensatory processes moderating these changes, and that can be utilized as a neurocognitive “stress test” for early detection of AD. For questions, please contact Laura Korthauer@brown.edu or Elena_Festa@brown.edu |
| Exosomes in Early Alzheimer's Disease | This study will define molecular markers of Alzheimer pathology in salivary and plasma exosomes of people with Alzheimer's disease and mild cognitive impairment. For questions, please contact Charles_Denby@lifespan.org |
| Delirium Watch in Patients with Intracranial Hemorrhage | The main premise of this study is to define a novel, streamlined approach to delirium detection in post stroke patients with the potential for broad applicability regardless of underlying neurological deficit. We hypothesize that monitoring for fluctuations in level of consciousness alone will be comparable to daily expert assessments in identifying patients with delirium after acute stroke. The proposed approach will also incorporate assessments of motor activity and sleep cycle disturbance in an attempt to increase sensitivity. Through the use of innovative technology, wrist actigraphy, we will attempt to augment the identification of delirium by quantifying measurements of limb movement. The main goal of this pilot proposal is to generate preliminary data to demonstrate the feasibility of detecting delirium in patients with acute stroke. For questions, please contact Ashley.Schomer@lifespan.org |
| Cognitive function and depression in Epilepsy | Many patients with epilepsy experience depression. The relationship between epilepsy and depression is unclear. The goal of the study is to better understand if certain aspects of cognitive functioning (i.e., executive dysfunction) may place an individual at greater risk for depression. Results may lead to better identification of individuals at risk for depression and inform future treatments for depression in patients with epilepsy. For questions, please contact AEng@lifespan.org or (401)444-9979 |
| Family Functioning and Quality of Life in Patients with Epilepsy | Patients and their families are currently participating in this year-long study that looks at the relationships between family functioning, quality of life, and symptoms of epilepsy. The information that we collect from this study will help us better understand how symptoms of epilepsy affect family life. This information will help us to provide better treatment for patients and their families. For questions, please contact AEng@lifespan.org or (401)444-9979 |
| Wireless EEG in Migraine | We are recruiting established patients in the Brown Neurology department who have a history of migraine headache, better understand what happens to brain waves during a migraine attack, and in migraine sufferers in general. Eligible subjects are between ages 18 and 55, can understand/read/write English, and have migraine. This study is sponsored by the Carney Institute for Brain Science, Brown University. If you are interested in participating, please contact Muhammad_Edhi@brown.edu |
Multicenter Clinical Trials
| Name | Description and Contact Info |
|---|---|
| Memory Disorders/Alzheimer's Disease | If you're interested in participating in one of your research trials, please contact Terry Fogerty at (401) 606-4664 or email memory@lifespan.org |
| CHARM | The primary objective is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI. For questions, please contact Ashley.Schomer@lifespan.org |
| ARCADIA | To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy. For questions, please contact Ashley.Schomer@lifespan.org |
| TIMELESS | This study will evaluate the efficacy and safety of tenecteplase compared with placebo in patients with acute ischemic stroke (AIS). All patients will receive standard-of-care therapy according to American Heart Association / American Stroke Association clinical guidelines (2018). To determine eligibility for randomization, all patients will undergo multimodal CT or MRI at baseline. Only patients with a vessel occlusion (ICA or MCA) and penumbral tissue will be randomized. For questions, please contact Ashley.Schomer@lifespan.org |
| ESCAPE-NA1 | The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects who are hospitalized with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization. For questions, please contact SMFoley@Lifespan.org |
| MaRISS | The objective of this study is to determine the 90-day outcomes of mild and rapidly improving ischemic stroke. For questions, please contact Ashley.Schomer@lifespan.org |
| ARAMIS | The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice. For questions, please contact Ashley.Schomer@lifespan.org |
| INTREPID | This study will assess the impact of fever prevention on fever burden and short and long-term neurologic outcomes in hospitalized brain injured patients. Half of the subjects will undergo fever prevention using a targeted temperature management system and half of the subjects will be treated for fever should it develop. For questions, please contact Ashley.Schomer@lifespan.org |
| StEP | This study involves a randomized controlled trial to test the feasibility, acceptability, and efficacy of a mobile health (mHealth)-enhanced physical activity (PA) intervention to increase daily bout-related and total moderate-intensity PA and to reduce sedentary behavior (SB) in non-physically impaired patients with ischemic stroke or transient ischemic attack (TIA). For questions, please contact Ashley.Schomer@lifespan.org |
| CLARITY-AD | Phase 3, multicenter trial to evaluate the efficacy of BAN2401 in participants with early Alzheimer's diseaseas well as the long-term safety and tolerability of BAN240 over 78 weeks. For questions, please contact Terry Fogerty at 401-606-4664 or email memory@lifespan.org |
| TRC-PAD | This study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into Alzheimer's disease preventiontrials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. For questions, please contact Terry Fogerty at 401-606-4664 or email memory@lifespan.org |
| ADNI-3 | This study is to develop improved brain imaging and biomarker methods in people with Alzheimer's disease, mild cognitive impairment, and normal elderly by acquiring high quality longitudinal data tha will be shared with the worl wide research community. For questions, please contact Terry Fogerty at 401-606-4664 or email memory@lifespan.org |
| Providence VA Medical Center | Multiple clinical trials are offered for veterans for alcohol abuse, epilepsy, ALS, pain, and mental health For questions, please contact VA Medical Center |